Luis Ruilope

Summary

Country: Spain

Publications

  1. ncbi Blood pressure lowering or selection of antihypertensive agent: which is more important?
    Luis M Ruilope
    Nephrol Dial Transplant 21:843-5. 2006
  2. ncbi Blood pressure control in patients with comorbidities
    Roland E Schmieder
    Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany
    J Clin Hypertens (Greenwich) 10:624-31. 2008
  3. ncbi Renal participation in cardiovascular risk in essential hypertension
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Expert Rev Cardiovasc Ther 1:309-15. 2003
  4. ncbi Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Curr Hypertens Rep 4:261-4. 2002
  5. ncbi Renal protection by antihypertensive therapy
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain
    Curr Hypertens Rep 4:324-8. 2002
  6. ncbi ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, 28041, Spain
    J Renin Angiotensin Aldosterone Syst 4:74-9. 2003
  7. ncbi The kidney as a sensor of cardiovascular risk in essential hypertension
    Luis M Ruilope
    Unidad de Hipertension, Servicio de Nefrologia, Hospital 12 de Octubre, Madrid, Spain
    J Am Soc Nephrol 13:S165-8. 2002
  8. ncbi Eprosartan for the treatment of hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
    Expert Opin Pharmacother 4:107-14. 2003
  9. ncbi Cardiovascular therapy in patients with renal insufficiency
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Cardiovasc Drugs Ther 16:497-501. 2002
  10. ncbi Lessons from trials in hypertensive type 2 diabetic patients
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain
    Curr Hypertens Rep 5:322-8. 2003

Collaborators

Detail Information

Publications73

  1. ncbi Blood pressure lowering or selection of antihypertensive agent: which is more important?
    Luis M Ruilope
    Nephrol Dial Transplant 21:843-5. 2006
  2. ncbi Blood pressure control in patients with comorbidities
    Roland E Schmieder
    Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany
    J Clin Hypertens (Greenwich) 10:624-31. 2008
    ..Not all available antihypertensives are equally effective in controlling BP over 24 hours, and some may exacerbate underlying metabolic abnormalities...
  3. ncbi Renal participation in cardiovascular risk in essential hypertension
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Expert Rev Cardiovasc Ther 1:309-15. 2003
    ....
  4. ncbi Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Curr Hypertens Rep 4:261-4. 2002
  5. ncbi Renal protection by antihypertensive therapy
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain
    Curr Hypertens Rep 4:324-8. 2002
    ..The control of other associated risk factors is also required, in particular smoking and lipids...
  6. ncbi ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, 28041, Spain
    J Renin Angiotensin Aldosterone Syst 4:74-9. 2003
    ..All these facts led to the conclusion that both ACE-Is and ARBs can be considered when both renal and cardiovascular protection are aimed for in Type 2 diabetic patients...
  7. ncbi The kidney as a sensor of cardiovascular risk in essential hypertension
    Luis M Ruilope
    Unidad de Hipertension, Servicio de Nefrologia, Hospital 12 de Octubre, Madrid, Spain
    J Am Soc Nephrol 13:S165-8. 2002
    ..Prevention and protection of renal and cardiovascular damage in these patients will be one of the most relevant tasks in the future...
  8. ncbi Eprosartan for the treatment of hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
    Expert Opin Pharmacother 4:107-14. 2003
    ..Eprosartan is safe, effective and well-tolerated in long-term treatment, either as a monotherapy or in combination with other antihypertensive drugs such as hydrochlorothiazide...
  9. ncbi Cardiovascular therapy in patients with renal insufficiency
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Cardiovasc Drugs Ther 16:497-501. 2002
    ..Besides this, strict control of associated cardiovascular risk factors is also required...
  10. ncbi Lessons from trials in hypertensive type 2 diabetic patients
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain
    Curr Hypertens Rep 5:322-8. 2003
    ..However, by attaining normal blood pressure levels (< 130/80 mm Hg), better preservation of glomerular filtration rate does not seem to be insured...
  11. ncbi New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
    L M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Renin Angiotensin Aldosterone Syst 1:S29-31. 2000
    ..Unlike ACE inhibition, ARB treatment leads to no initial reduction in GFR, thus valsartan may be a better agent for the control of BP, with greater renal protection...
  12. ncbi Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Clin Ther 25:3044-64. 2003
    ..Preventing or delaying the progression of renal disease from microalbuminuria to nephropathy, and ultimately, to ESRD is thus a crucial goal of DM management...
  13. ncbi Long-term protection in at-risk hypertensive patients--a role for nifedipine GITS?
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Blood Press 11:106-9. 2002
    ..The results from INSIGHT support incorporating nifedipine GITS in the management of high-risk hypertensive patients to prevent atherosclerosis-related illness and death...
  14. ncbi Kidney dysfunction: a sensitive predictor of cardiovascular risk
    L M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Am J Hypertens 14:213S-217S. 2001
    ..The parameters commonly used to evaluate renal function have to be considered in any stratification of cardiovascular risk in hypertensive and heart failure patients...
  15. ncbi Hyperuricemia and renal function
    L M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, 28041, Madrid, Spain
    Curr Hypertens Rep 3:197-202. 2001
    ..For this reason, the predictive capacity of uric acid could be partly dependent on the fact that hyperuricemia runs in parallel with a deranged renal function...
  16. ncbi Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study
    L M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
    J Am Soc Nephrol 12:218-25. 2001
    ....
  17. ncbi The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue?
    L M Ruilope
    Unidad de Hipertension, Servicio de Nefrologia, Hospital 12 de Octubre, Madrid, Spain
    Curr Hypertens Rep 3:419-21. 2001
    ....
  18. ncbi Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease
    L M Ruilope
    Hospital 12 de Octubre, Servicio de Nefrologia, Madrid, Spain
    J Hypertens 18:89-95. 2000
    ..Such enhanced suppression might be of benefit for patients exhibiting a progressive decline in renal function because of chronic renal disease...
  19. ncbi Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use?
    L M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Hypertension 38:537-42. 2001
    ..The question remains for the time being largely unanswered...
  20. ncbi Renal function: the Cinderella of cardiovascular risk profile
    L M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    J Am Coll Cardiol 38:1782-7. 2001
    ..Renal outcome is also improved by ACE inhibition after an MI. Finally, renal and cardiovascular outcome seem to run in parallel in all these situations...
  21. ncbi Renal participation in cardiovascular risk in essential hypertension
    L M Ruilope
    Unit of Hypertension, Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain
    Blood Press 10:322-6. 2001
    ..Prevention and protection of renal and cardiovascular damage in these patients will be one of the most relevant healt care tasks in the future...
  22. doi Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Clin Hypertens (Greenwich) 12:422-30. 2010
    ....
  23. ncbi The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Blood Press 16:72-9. 2007
    ....
  24. ncbi Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
    Hermann Haller
    Nephrology Section, Hanover Medical School, Hanover, Germany
    J Hypertens 24:403-8. 2006
    ..The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease...
  25. ncbi Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
    Clin Ther 27:578-87. 2005
    ..Recent antihypertensive treatment guidelines recommend greater use of combination therapies...
  26. ncbi Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Fundam Clin Pharmacol 19:429-37. 2005
    ..The high prevalence of chronic kidney disease in the general and in the hypertensive populations implies the need for an integrative therapeutic approach to fully protect renal and cardiovascular systems simultaneously...
  27. ncbi Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax)
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens Suppl 24:S9-12. 2006
    ..The fixed combination of perindopril/indapamide can greatly help clinicians in achieving the above goals, using Preterax in the early and BiPreterax in the late stages of nephropathy...
  28. ncbi Chronic kidney disease as a situation of high added risk in hypertensive patients
    Julian Segura
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, 28041 Madrid, Spain
    J Am Soc Nephrol 17:S136-40. 2006
    ..This paper briefly reviews the most recent evidences about pharmacologic therapies in high-risk patients, focusing on benefits related to improvement of cardiovascular risk factors in hypertensive patients with chronic kidney disease...
  29. ncbi Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies
    Pedro Aranda
    Nephrology Department, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Am J Kidney Dis 46:1074-9. 2005
    ....
  30. ncbi Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study
    Rafael Marín
    Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
    J Hypertens 24:395-402. 2006
    ..The present study was designed for assessment of control rates of blood pressure in patients with CRI. Secondary objectives included evaluation of the control rates of proteinuria and cardiovascular comorbidities...
  31. ncbi Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting
    Paolo Palatini
    Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy
    J Hypertens 24:603-10. 2006
  32. ncbi Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
    George L Bakris
    Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 24:2047-55. 2006
    ..To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control...
  33. ncbi Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial
    Luis M Ruilope
    Internal Medicine, Comlutense University, Madrid, Spain
    J Renin Angiotensin Aldosterone Syst 7:S8-11. 2006
    ..In addition, combination therapy resulted in a trend towards more favourable outcomes with respect to pro-thrombotic and proinflammatory markers than amlodipine alone...
  34. doi The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy
    Luis M Ruilope
    Servicio de Nefrologia, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Clin Exp Hypertens 30:397-414. 2008
    ..ARBs decrease overall risk of CV and end-organ disease, CVD-related mortality, and cerebrovascular events in patients with hypertension...
  35. ncbi Angiotensin receptor blockers: RAAS blockade and renoprotection
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Curr Med Res Opin 24:1285-93. 2008
    ..The central role of the renin-angiotensin-aldosterone system (RAAS) in hypertension and renal disease has led to interest in the ability of RAAS-blocking agents to provide benefits beyond blood pressure control...
  36. doi Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 26:357-67. 2008
    ..This analysis assessed the impact of rimonabant on blood pressure in the pooled population from four large trials with similar design - the Rimonabant-In-Obesity (RIO) programme...
  37. ncbi Glucose metabolism in patients with essential hypertension
    Juan Garcia-Puig
    Division of Internal Medicine at Hospital Universitario La Paz, Madrid, Spain
    Am J Med 119:318-26. 2006
    ..Arterial hypertension is an insulin-resistant condition that has been associated with an increased incidence of diabetes. We assessed the prevalence of glucose abnormalities in a population of patients with essential hypertension...
  38. ncbi Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Curr Opin Nephrol Hypertens 16:422-6. 2007
    ....
  39. pmc Trandolapril/verapamil combination in hypertensive diabetic patients
    Jose A Garcia Donaire
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Vasc Health Risk Manag 3:77-82. 2007
    ..This combination can be considered as an effective therapy for the diabetic hypertensive population...
  40. ncbi Angiotensin receptor blockade in diabetic renal disease--focus on candesartan
    Jose A Garcia Donaire
    Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    Diabetes Res Clin Pract 76:S22-30. 2007
    ..When given in addition to an ACE inhibitor (dual blockade), reductions in UAE of 25-35% relative to ACE inhibitor monotherapy have been found...
  41. ncbi Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes
    Roland E Schmieder
    Department of Nephrology and Hypertension, University of Erlangen Nurnberg, Erlangen, Germany
    Diabetes Care 30:1351-6. 2007
    ..The aim of this study was to analyze the effects of renin-angiotensin system (RAS) blockade on renal endothelial function...
  42. ncbi Clinical trials in nephrology: success or failure
    Jose A Garcia-Donaire
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Madrid, Spain
    Curr Opin Nephrol Hypertens 16:59-63. 2007
    ..Suppression of the rennin-angiotensin-aldosterone system should also be considered in any patient with chronic kidney disease, in particular if albuminuria is present...
  43. ncbi Obesity, essential hypertension and renin-angiotensin system
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    Public Health Nutr 10:1151-5. 2007
    ..This review discusses the role of RAS in the relationship between obesity, essential hypertension and insulin resistance...
  44. ncbi Left ventricular hypertrophy and clinical outcomes in hypertensive patients
    Luis M Ruilope
    Hospital 12 de Octubre, Avda de Cordoba s n, Madrid, Spain
    Am J Hypertens 21:500-8. 2008
    ..Guidelines, therefore, have recommended these drug classes for the treatment of hypertensive patients with LVH...
  45. ncbi Calcium channel blockers and renal protection: insights from the latest clinical trials
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Am Soc Nephrol 16:S64-6. 2005
    ....
  46. ncbi 24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain bNovartis AG, Basel, Switzerland
    Blood Press Monit 10:85-91. 2005
    ..There is a lack of data on the effects of angiotensin-receptor blocker and diuretic combinations on ambulatory blood pressure (ABP) in hypertensive patients with additional cardiovascular risk factors...
  47. ncbi [PREVENCAT study: control of cardiovascular risk in primary care]
    Luis A Alvarez-Sala
    Departamento de Medicina, Hospital General Universitario Gregorio Maranon, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    Med Clin (Barc) 124:406-10. 2005
    ....
  48. ncbi Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses
    Juliá Segura
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Madrid, 28041, Spain
    J Renin Angiotensin Aldosterone Syst 4:43-7. 2003
    ..Both ACE-I and ARB were titrated as monotherapy up to the maximal recommended dose...
  49. ncbi Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)
    Giuseppe Mancia
    University of Milano Bicocca, St Gerardo Hospital, Monza, Milan, Italy
    Hypertension 41:431-6. 2003
    ..Our results suggest that nifedipine could be considered as first-line therapy for hypertensive diabetics...
  50. ncbi Hypertension magnitude and management in the elderly population of Spain
    Jose R Banegas
    Department of Preventive Medicine and Public Health, Autonomous University of Madrid, Madrid, Spain
    J Hypertens 20:2157-64. 2002
    ..The present study assessed the prevalence, awareness, treatment and control of hypertension among the elderly population of Spain...
  51. ncbi Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?
    Alberto Zanchetti
    Centro di Fisiologia Clinica e Ipertensione, Universita di Milano, Ospedale Maggiore and Istituto Auxologico Italiano, Milano, Italy
    J Hypertens 20:2099-110. 2002
    ..Patients with type-2 diabetes have a high prevalence of hypertension and show an elevated incidence of cardiovascular events and nephropathy...
  52. ncbi N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients
    Vivencio Barrios
    Department of Cardiology, Hospital Ramon y Cajal, Madrid, Spain
    Blood Press 11:235-9. 2002
    ..This effect may be mediated by an NO-dependent mechanism, probably through the protective effect of NAC on NO oxidation...
  53. ncbi The Framingham prediction rule is not valid in a European population of treated hypertensive patients
    Sylvie Bastuji-Garin
    Department of Public Health, Henri Mondor Hospital, AP HP, Paris XII University, Creteil, France
    J Hypertens 20:1973-80. 2002
    ..Stratification of population groups according to cardiovascular risk level is recommended for primary prevention...
  54. ncbi Renal dysfunction as a cardiovascular risk factor
    Eberhard Ritz
    Department of Internal Medicine, University of Heidelberg, Bergheimer Strasse 58, Germany
    Curr Hypertens Rep 4:365-8. 2002
    ..Epidemiologic information suggests that renal and cardiovascular outcome run parallel in this segment of the population...
  55. ncbi Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad
    Vivencio Barrios
    Servicio de Cardiologia, Hospital Ramon y Cajal, Madrid, Spain
    Blood Press 11:95-100. 2002
    ..With the aim to determine the efficacy and tolerability of this drug in usual clinical practice we performed the ELYPSE trial...
  56. ncbi ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Complutense University, Madrid, Spain
    Am J Hypertens 15:367-71. 2002
    ....
  57. ncbi Losartan titration versus diuretic combination in type 2 diabetic patients
    Pedro Luis de Pablos-Velasco
    H General de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain
    J Hypertens 20:715-9. 2002
    ..5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks...
  58. ncbi Valsartan improves fibrinolytic balance in atherosclerotic rabbits
    M Pilar Oubina
    Departmento de Fisiologia, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    J Hypertens 20:303-10. 2002
    ..To examine the long-term effects of the angiotensin type I (AT1) receptor antagonist, valsartan, on fibrinolytic balance, coagulation parameters, endothelial function and structural alterations in atherosclerotic rabbits...
  59. ncbi Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors
    Christopher R Palmer
    JAMA 289:2066-7; author reply 2069-70. 2003
  60. ncbi How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    Curr Hypertens Rep 5:426-9. 2003
    ..The aim of this paper is to briefly review the evidence in favor of uptitration of either class of inhibitors of the renin-angiotensin system as compared with the combination of the two for the control of either BP or proteinuria...
  61. ncbi Recent developments in the treatment of type 2 diabetes mellitus
    Luis M Ruilope
    Hospital 12 de Octubre, Servicio de Nefrologia, Madrid, Spain
    Cardiovasc Drugs Ther 17:151-8. 2003
    ..Agents that interfere with the renin-angiotensin system, particularly angiotensin-receptor blockers, may have particular benefits on end-organs in diabetic patients...
  62. ncbi Renal endpoints in hypertension trials
    Helle Christiansen
    Unidad de Hipertension, Madrid, Spain
    Clin Exp Hypertens 26:721-6. 2004
    ..This paper describes the detection, prevalence and relevance of minor alterations in the stratification of cardiovascular risk in the hypertensive patient...
  63. ncbi Hope in Life and Value of blood pressure control
    Luis M Ruilope
    J Hypertens 22:2265-6. 2004
  64. ncbi Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial
    Peter W de Leeuw
    Department of Medicine, University Hospital Maastricht, Maastricht, The Netherlands
    Arch Intern Med 164:2459-64. 2004
    ..To assess this role of renal function in more detail, we studied the evolution of renal function and the relationship of renal function with mortality and morbidity in the Intervention as a Goal in Hypertension Treatment (INSIGHT) study...
  65. ncbi Cerebrovascular protection and antihypertensive therapy
    Jose A Garcia-Donaire
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Curr Opin Nephrol Hypertens 13:507-12. 2004
    ..In addition, an overview of stroke pathogenesis is given and its relationship with treatment action mechanisms reviewed...
  66. ncbi Development of chronic kidney disease in essential hypertension during long-term therapy
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Curr Opin Nephrol Hypertens 13:495-500. 2004
    ..This review examines the relevance of the development of chronic kidney disease in long-term hypertensive patients on the cardiovascular prognosis...
  67. ncbi Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension
    Carlos Calvo
    Hypertension and Vascular Risk Unit, Hospital Clinico Universitario, Santiago de Compostela, Madrid, Spain
    J Hypertens 22:837-46. 2004
    ..This trial investigated and compared the antihypertensive efficacy of telmisartan and valsartan, two angiotensin II receptor blockers, used in monotherapy at their maximum recommended dose in hypertensive patients...
  68. ncbi Blood pressure control and physician management of hypertension in hospital hypertension units in Spain
    Jose R Banegas
    Department of Preventive Medicine and Public Health, of Medicine, Universidad Autonoma de Madrid, Spain
    Hypertension 43:1338-44. 2004
    ..Patients at high risk, with diabetes or proteinuria, warrant focused attention. Moreover, a more aggressive behavior of doctors treating uncontrolled hypertension is needed...
  69. ncbi Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 du Octubre, Madrid, Spain
    J Hypertens 22:217-22. 2004
    ....
  70. ncbi Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension
    Carlos Campo
    Unidad de Hipertension, Departamento de Bioquimica, Hospital Universitario 12 de Octubre, Madrid, Spain
    Blood Press 12:277-83. 2003
    ..Hyperuricemia has been shown to be associated with an increased risk of cardiovascular disease in hypertensive patients in some but not in all epidemiological studies in which this relationship has been investigated...
  71. ncbi Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension
    Carlos Campo
    Hypertension Unit, Hospital Universitario 12 de Octubre, Madrid ES 28041, Spain
    Blood Press Suppl 2:16-21. 2003
    ..Therefore, in patients not controlled with monotherapy, doxazosin GITS can be considered an alternative to the addition of thiazide diuretics...
  72. ncbi New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial
    Cristina Sierra
    Hypertension Units, Hospital Clinic of Barcelona, Madrid, Spain
    J Renin Angiotensin Aldosterone Syst 4:169-70. 2003
    ..Long-term studies are required to determine the relevance of development of new-onset diabetes in treated hypertensive patients...
  73. ncbi Factors influencing the systolic blood pressure response to drug therapy
    Carlos Campo
    Hypertension Unit, 12 de Octubre University Hospital, Avda de Cordoba s n, Madrid, 280041 Spain
    J Clin Hypertens (Greenwich) 4:35-40. 2002
    ..It appears that the profile of patients with a poorer therapeutic response includes a greater severity of hypertension and/or the presence of cardiovascular disease...